Kymera Therapeutics, Inc. $KYMR Stock Holdings Trimmed by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors cut its Kymera Therapeutics stake by 5% in the first quarter, selling 31,148 shares and retaining 592,879 shares worth approximately $49.4 million, or 0.72% of the company.
• Kymera insiders have sold heavily recently, including Director Bruce Booth’s $51.6 million sale and CEO Nello Mainolfi’s $9.2 million sale. Insiders sold 3.61 million shares worth $387.8 million over the past 90 days.
• Wall Street’s outlook remains generally positive, with 20 Buy ratings, two Holds and one Sell; the stock has a “Moderate Buy” consensus and an average price target of $124.48. Kymera also reported quarterly revenue growth of 55.5% and better-than-expected adjusted earnings.

Dimensional Fund Advisors LP lessened its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.0% in the first quarter, according to its most recent filing with the SEC. The firm owned 592,879 shares of the company's stock after selling 31,148 shares during the quarter. Dimensional Fund Advisors LP owned about 0.72% of Kymera Therapeutics worth $49,359,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Smartleaf Asset Management LLC increased its holdings in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC lifted its holdings in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after purchasing an additional 349 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Kymera Therapeutics in the fourth quarter worth about $63,000. Osaic Holdings Inc. lifted its holdings in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after purchasing an additional 1,083 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Kymera Therapeutics in the 2nd quarter valued at about $73,000.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bruce Booth sold 467,878 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the completion of the sale, the director directly owned 472,267 shares of the company's stock, valued at $52,086,327.43. This represents a 49.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 80,000 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the sale, the chief executive officer owned 666,568 shares of the company's stock, valued at $76,848,624.72. The trade was a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 3,607,813 shares of company stock worth $387,818,004. 15.98% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have commented on KYMR. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 2nd. Brookline Capital Markets reaffirmed a "buy" rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Canaccord Genuity Group increased their price objective on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a "buy" rating in a report on Friday, June 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kymera Therapeutics in a research note on Friday, July 17th. Finally, Mizuho boosted their target price on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an "outperform" rating in a report on Thursday, July 16th. Twenty analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $124.48.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $103.40 on Monday. The business's 50-day moving average price is $98.92 and its 200 day moving average price is $87.77. The firm has a market cap of $8.51 billion, a P/E ratio of -28.96 and a beta of 1.95. Kymera Therapeutics, Inc. has a 52-week low of $36.65 and a 52-week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million for the quarter, compared to analysts' expectations of $8.27 million. During the same period in the previous year, the business earned ($0.82) earnings per share. Kymera Therapeutics's revenue for the quarter was up 55.5% compared to the same quarter last year. Sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.29 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source